Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients
Mary Angelin,Padmavathi Gopinath,Vijaya Raghavan,Rangaswamy Thara,Faraz Ahmad,Arasamabattu Munirajan,Ravi Sudesh
DOI: https://doi.org/10.2147/ndt.s466502
IF: 2.989
2024-07-20
Neuropsychiatric Disease and Treatment
Abstract:Mary Angelin, 1 Padmavathi Gopinath, 1 Vijaya Raghavan, 1, 2 Rangaswamy Thara, 2 Faraz Ahmad, 3 Arasamabattu Kannan Munirajan, 1 Ravi Sudesh 4 1 Department of Genetics, University of Madras, Dr ALM PG Institute of Basic Medical Sciences, Taramani Campus, Chennai, Tamil Nadu, 600 113, India; 2 Schizophrenia Research Foundation, Chennai, Tamil Nadu, 600 101, India; 3 Department of Biotechnology, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India; 4 Department of Biomedical Sciences, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India Correspondence: Ravi Sudesh, Department of Biomedical Sciences, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India, Tel +91-9176028134, Email ; Arasamabattu Kannan Munirajan, Department of Genetics, Dr. ALM PG Institute Basic Medical Sciences, University of Madras, Taramani, Chennai, Tamil Nadu, 600 113, India, Tel +91-44-24547064 ; +91-9444460136, Email ; Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A The flow of genetic information is modulated by several regulatory components that ensure homeostasis of the biological system. In addition to this regulatory network, several heritable chemical modifications impact gene expression without altering the DNA sequence, forming the basis of epigenetics. 1–4 The epigenetic marks/signatures primarily include nucleic acid methylation, nucleosomal histone modifications, chromatin remodelling, and non-coding RNA regulation. 2,3,5 These epigenetic pathways, which can be influenced by environmental factors, operate independently to regulate the genome. Several studies have depicted the impacts of early life epigenetic stressors on different aspects of the central nervous system (CNS), viz. neurodevelopment, signalling and plasticity, regeneration, and higher-order functions of behaviour, memory, and cognition. However, the underlying molecular mechanisms linking epigenetic alterations and brain functions are yet to be completely discerned. Also, epigenetic changes as associative factors providing an interface between genotype and phenotype, for the development of complex neuropsychiatric disorders, are not understood completely. 6,7 Schizophrenia (SCZ) is one such chronic psychiatric disorder with a complex multimodal etiology, and affects an estimated 20 million people globally. 8 This heterogeneous debilitating disease is characterized by positive symptoms such as delusion and hallucinations, and negative symptoms such as anhedonia, apathy, and cognitive -Abstract Truncated-
psychiatry,clinical neurology